The Deal

Healthcare to Remain a Hotbed for PE Dealmaking: Bain & Company

Healthcare to Remain a Hotbed for PE Dealmaking: Bain & Company

Besides long-term trends including an aging population and the increasing prevalence of chronic disease, Bain & Company cited two other factors that are fueling investors' interest in North American healthcare assets.

  • aprile 22, 2019
  • Tempo di lettura min.

The Deal

Healthcare to Remain a Hotbed for PE Dealmaking: Bain & Company

A high level of dealflow from private equity firms in the healthcare sector is likely to continue at a rapid pace in 2019, according to consulting firm Bain & Company.

"We are quite bullish on the continued high level of activity in 2019 in healthcare PE," said Nirad Jain, a partner with Bain & Company who co-heads the global healthcare private equity and corporate M&A practices, in an interview on the heels of the release of Bain's Global Healthcare Private Equity and Corporate M&A Report 2019, which released Wednesday, April 17.

Last year, disclosed transaction values for healthcare PE deals totaled $63.1 billion globally, marking the highest level since 2006 and an increase from $42.6 billion in 2017, according to the report. 2018 saw eight transactions valued north of $2 billion, compared with four in 2017.